Nachrichten zur Ardelyx Inc. Aktie

Global Infectious Enteritis Treatment Market Projected to Nearly Double by 2034

Dublin, April 01, 2024 (GLOBE NEWSWIRE) -- The "Global Infectious Enteritis Treatment Market" report has been added to…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Ardelyx to Participate at the Cowen 44th Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx to Participate at the Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

: Ardelyx shares climb as kidney-disease drug gets green light from Japanese regulators

Ardelyx Inc. shares ARDX gained 6% premarket on Monday after the company announced that its partner Kyowa Kirin Co. Ltd.…

Cantor upgrades Ardelyx to overweight ahead of FDA decision on renal drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx GAAP EPS of -$0.08 beats by $0.04, revenue of $22.3M beats by $7.02M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3 million; Company currently expects 2023 full year IBSRELA net…

Form 10-Q ARDELYX, INC. For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K ARDELYX, INC. For: Aug 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

Conference call scheduled for 8:00 a.m. Eastern Time Conference call scheduled for 8:00 a.m. Eastern Time...…

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma Acceptance of NDA Submission triggers…

Insiderhandel: Chief Medical Officer verkauft Aktien von Ardelyx im Wert von 83.633$

Williams, Laura A. - Vorstand - Tag der Transaktion: 2023-06-27...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Insiderhandel: Vorstand verkauft Aktien von Ardelyx im Wert von 121.042$

Blanks, Robert - Vorstand - Tag der Transaktion: 2023-06-23...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

User Fee Goal Date: October 17, 2023 User Fee Goal Date: October 17, 2023...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...…

Ardelyx resubmits NDA for Xphozah to US FDA

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD)…

Ardelyx resubmits NDA to FDA for tenapanor for chronic kidney disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of…

dpa-AFX ProFeed